Cypherpunk Technologies （CYPH） shares soared as they debuted on the Nasdaq following the firm’s transition from a biotech company under Leap Therapeutics into a digital asset treasury company.
The company has already raised millions to start putting into Zcash （ZECUSD）， representing a calculated bet on privacy-focused cryptocurrencies as digital surveillance concerns intensify globally
At present,CYPH stock （formerly LPTX） is trading at well over 4x its price earlier this week.
Price-to-Book Ratio of 37x: Is it justified?
With Cypherpunk Technologies trading at a staggering price-to-book （P/B） ratio of 37, its recent closing price of $1.76 signals significant optimism compared to its US Biotech peers.
The price-to-book ratio measures how much investors are willing to pay for each dollar of net assets on the company’s balance sheet. For a biotech company with minimal revenue and ongoing unprofitability, this multiple is especially critical and can reflect either speculative growth expectations or risk tolerance.
Currently, Cypherpunk’s P/B is far above the US Biotech industry average of just 2.5. This outsized premium suggests the market is either pricing in transformational prospects from its digital asset pivot or embracing substantial risk. Relative to historical and sector norms, such a premium is difficult to justify given a lack of forecast revenue and negative earnings trends. In short, the market’s current enthusiasm appears well ahead of fundamental improvements.
Why CYPH Shares Aren’t Worth Chasing
Despite the initial excitement, investors are recommended caution in playing Cypherpunk stock on the Zcash rebranding.
Why? Mostly because the timing of this launch coincides with deteriorating cryptocurrency market conditions that present substantial headwinds.
Bitcoin （BTCUSD） decently crashed below the psychologically critical $100,000 level as institutional inflows weaken and the Federal Reserve’s rate cut expectations diminished in the aftermath of the government shutdown.
With over $1 billion in leveraged positions liquidated and market sentiment indicators reaching extreme fear levels of 15, the Zcash strategy may not prove as rewarding for CYPH as executives hope, at least in the near-term.
ZCash Headwinds Could Hurt CYPH Stock in 2026
Caution is warranted on buying CYPH shares following the aforementioned strategic pivot since ZCash itself faces significant technical challenges as well despite institutional interest in privacy.
Zcash is currently down some 30% from its recent peak near $750.
Moreover, privacy coins face more intense scrutiny from regulators concerned about compliance with anti-money laundering requirements.
This could in turn limit mainstream institutional adoption, creating another major hurdle for the firm’s recently launched Zcash treasury strategy to prove successful for the crypto penny stock.
What’s the Consensus Rating on Cypherpunk Technologies?
Wall Street analysts also believe the post-transformation rally in CYPH stock is overdone.
According to Barchart, the consensus rating on Cypherpunk shares currently sits at “Hold” only with the mean target of $1.25 indicating potential downside of some 30% from here.
Cypherpunk Technologies Inc. （CYPH） Description
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia （excluding Japan）， Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.